ARTH Stock News Arch Therapeutics Inc. (ARTH) 0.2050 07/26/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Arch Therapeutics Inc. (ARTH) 0.2050 $ARTH

Arch Therapeutics Announces Collaboration With University College Cork School of Pharmacy
Marketwire - Tue Jul 22, 7:31AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), has entered into a new collaboration agreement with the University College Cork (UCC) School of Pharmacy in Cork, Ireland, of the National University of Ireland (NUI), focusing on development of hemostasis and sealant products.

Arch Therapeutics Selects BSI as Its European Union Notified Body
Marketwire - Tue Jul 15, 7:31AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has selected the British Standards Institution ("BSI" as its Notified Body. A Notified Body is an organization that has been accredited by a member state of the European Union to assess whether a product meets certain preordained standards to receive a CE Mark designation.

Arch Therapeutics Appoints Richard Davis as Chief Financial Officer
Marketwire - Mon Jul 07, 5:07PM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has appointed Richard Davis as Chief Financial Officer and Treasurer as it continues to expand its team. Mr. Davis, who has worked as a consultant at Arch since April, has started full time in his new role effective today, July 7, 2014. The Company's current Chief Financial Officer and Treasurer, Alan Barber, has resigned from his position effective July 7, 2014 and has become an advisor to the Company.

Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at European Summit for Clinical Nanomedicine and Targeted Medicine in Basel, Switzerland on June 23
Marketwire - Mon Jun 16, 7:15AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announces that co-founder and inventing scientist Dr. Rutledge Ellis-Behnke will present his work using AC5(TM) at the Seventh Annual European Summit for Clinical Nanomedicine and Targeted Medicine in Basel, Switzerland on Monday, June 23.

Arch Therapeutics Inc. to Present at the LD MICRO Invitational 2014 on June 4th
Marketwire - Wed May 28, 8:03AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, MD, will present at the LD MICRO Invitational on Wednesday, June 4th, 2014 in Los Angeles, CA.

Arch Therapeutics Inc. to Present at the Third Annual Marcum MicroCap Conference
Marketwire - Tue May 27, 8:03AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced today that it will be a featured presenter at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New York City.

Arch Therapeutics Appoints Chirag Shah, PhD as Vice President of R&D Engineering and Quality Systems and Peter LaCrosse as Chief of Staff
Marketwire - Tue Apr 01, 7:03AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has appointed Chirag Shah, PhD as Vice President of Research and Development Engineering and Quality Systems, effective April 7, 2014, and has appointed Peter A. LaCrosse as Chief of Staff, effective immediately.

Arch Therapeutics Co-Founder Rutledge Ellis-Behnke, PhD Presents at Two Scientific Meetings in March
Marketwire - Wed Mar 26, 8:03AM CDT
Rutledge Ellis-Behnke, PhD, co-founder and inventing scientist at Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or "the Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, presents his work using AC5(TM) at two scientific meetings.

IPOs and Transactions: March 17 - 21
PR Newswire - Mon Mar 24, 11:30AM CDT
There were 56 transactions filed with the SEC last week. Highlighted corporations and law firms include:

Arch Therapeutics to Present at The Wall Street Analyst Forum Institutional Investor Conference
Marketwire - Wed Feb 26, 8:01AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, MD, is scheduled to present a corporate overview at The Wall Street Analyst Forum Conference in Manhattan at The University Club of NYC on Monday, March 3rd at 12:05 PM EST.

10-Q: ARCH THERAPEUTICS, INC.
Edgar Online - Fri Feb 14, 7:42AM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Arch Therapeutics Secures $2.85 Million Private Placement
Marketwire - Mon Feb 10, 8:02AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care has closed a previously announced private placement to accredited individual and institutional investors (the "Investors" .

OTC Daily Alert Stock Watch - Arch Therapeutics, Inc. (OTCQB: ARTH)
WorldStockWire - Wed Feb 05, 4:15AM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Arch Therapeutics Announces $2.85 Million Private Placement
Marketwire - Fri Jan 31, 5:00AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce today its private placement to institutional and high net worth investors of an aggregate of 11,400,000 shares of common stock at $0.25 per share, pursuant to the terms of a securities purchase agreement dated January 30, 2014. The private placement is expected to close on or about February 4, 2014, subject to customary closing conditions.

Arch Therapeutics Presents 2014 Milestones During Live Webcast
Marketwire - Wed Jan 22, 10:01AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, M.D., presented its calendar year 2014 milestone targets during a live audio and high-definition video webcast on Wednesday, January 22 at 10:30AM Eastern Time from the Noble Financial Capital Markets' Tenth Annual Equity Conference in South Florida.

Arch Therapeutics to Present Status Update and Milestone Overview at Noble Financial Capital Markets' Tenth Annual Equity Conference
Marketwire - Tue Jan 14, 8:03AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, M.D., is scheduled to present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference in Sandpiper Bay, Florida, on Wednesday, January 22 at 10:30AM Eastern Time.

Arch Therapeutics to Webcast Live From the Biotech Showcase Investor Conference
Marketwire - Wed Jan 08, 8:02AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Terrence W. Norchi, M.D., CEO of Arch Therapeutics will present at The Biotech Showcase(TM) 2014 conference on Monday, January 13th, at 5:00PM PST. Attendees will find the presentation scheduled for "Track C" in the Mission II room at that time. Dr. Norchi's presentation will provide insights into the Company's ongoing activities to commercially develop novel technologies into a suite of new products targeting markets of unmet clinical need.

Arch Therapeutics Announces Participation at the 2013 Boulder Peptide Symposium in Colorado September 25-27
Marketwire - Fri Sep 20, 8:01AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , today announced it will be featured as a presenting company at the Boulder Peptide Symposium 2013. The conference is being held September 25-27, 2013, at the St Julien Hotel in Boulder, Colorado.

Arch Therapeutics Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
Marketwire - Tue Sep 03, 8:01AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference. The conference, sponsored by H.C. Wainwright & Co., LLC, is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City.

Arch Therapeutics Announces Plans for Upcoming Activities
Marketwire - Tue Aug 06, 2:06PM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life science company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to provide a brief review of proposed future activities.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 94

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 209

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 17

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 139

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 203

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 97

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 167

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 58

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategies for Trading Key Stocks: SPY, AAPL & More

Updated Category News Views 72

Morning Trading Insights for Major Stocks Good Morning Traders! In today's Market Clubhouse Morning Memo, we'll take a closer look at key stocks such as SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA. Keeping an eye on these stocks could be crucial for your trading strategy today. Using our proprietary formula exclusive to Market Clubhouse, we determine price levels...

Continue Reading
Precious Metals Shine as Gold Miners Show Strong Growth

Updated Category News Views 194

Gold Miners Surge Ahead of Broader Metals Market The precious metals sector is currently thriving, with gold miners exhibiting significant growth and surpassing previous resistance levels. This encouraging trend is apparent as the GDX index, which tracks the performance of gold mining companies, continues its upward trajectory. Comparison of Junior and Regular Miners...

Continue Reading
MacGregor Revamps Fleet for Wallenius Wilhelmsen Deal

Updated Category News Views 207

MacGregor's Big Move: Retrofitting 35 Vessels I'll tell you something right off the bat—the maritime industry's always got some sea changes brewing, but this latest one’s a real head-turner. MacGregor, those wizards of heavy machinery, have sealed a deal to retrofit 35 ships for Wallenius Wilhelmsen. We’re talking a serious overhaul here, folks, with programmable...

Continue Reading
Nokia Corporation Announces Share Transfer for Incentive Plans

Updated Category News Views 207

Nokia Corporation's Recent Share Transfers Nokia Corporation has recently made significant changes involving its own shares, reflecting its ongoing commitment to its equity-based incentive plans. A total of 5,348 Nokia shares (Helsinki:NOKIA) were transferred today to participants of these plans, emphasizing the company's engagement with its employees and stakeholders....

Continue Reading
Director Peter Hammond Acquires Shares in Adsure Services PLC

Updated Category News Views 271

Director's Share Purchase Signals Confidence In a notable move reflecting confidence in future growth, Adsure Services PLC (LSE:ADS) revealed that director Peter John Hammond has acquired 29 ordinary shares priced at £0.21 each. This acquisition has drawn attention due to its nature as a notification under the UK Market Abuse Regulation guidelines. Details of the...

Continue Reading